Last update :
16/06/2024
Antimuscarinic   Scopolamine hydrobromide  
Injection
Nasal drops
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Dispamine Iran
Escopolamina Chile
Hyoscine Great Britain, Ireland, Malaysia
Lorcopan Iran
Scopolamine Belgium, France
Scopolamine hydrobromide United States of America
Stability of mixtures   Injection   Stability of mixtures : Scopolamine hydrobromide     
Container Solvent Concentration Compound Temperature Storage Duration of stability References
Polypropylen Syringe Sodium chloride 0,9% 0,0052 mg/ml
Injection   Scopolamine hydrobromide   
Injection   Bumetanide 0,0417 mg/ml
2-8°C
18 Day
Not specified 4691
Level of evidence C+
Polypropylen Syringe Sodium chloride 0,9% 0,0312 mg/ml
Injection   Scopolamine hydrobromide   
Injection   Bumetanide 0,125 mg/ml
2-8°C
18 Day
Not specified 4691
Level of evidence C+
Polypropylen Syringe Sodium chloride 0,9% 0,04 mg/ml
Injection   Scopolamine hydrobromide   
Injection   Famotidine 0,4 mg/ml
Injection   Haloperidol lactate 0,5 mg/ml
Injection   Dimenhydrinate 5 mg/ml
Injection   Hydromorphone hydrochloride 10 mg/ml
25°C
12 Hour
Not specified 2166
Polypropylen Syringe Sodium chloride 0,9% 0,04 mg/ml
Injection   Scopolamine hydrobromide   
Injection   Famotidine 0,4 mg/ml
Injection   Haloperidol lactate 0,5 mg/ml
Injection   Dimenhydrinate 5 mg/ml
Injection   Hydromorphone hydrochloride 10 mg/ml
4°C
12 Hour
Not specified 2166

  Mentions Légales